نتائج بحث المؤلف

1

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial

بواسطة Giorgio V. Scagliotti, Maciej Krzakowski, Aleksandra Szczesna, Janos Strausz, Anatoly Makhson, Martin Reck, Rafal F. Wierzbicki, Istvan Albert, Michael Thomas, Jose Elias Abrao Miziara, Zsolt S. Papai, Nina Karaseva, Sumitra Thongprasert, Elsa Dalmau Portulas, Joachim Von Pawel, Ke Zhang, Paulina Selaru, Lesley Tye, Richard C. Chao, Ramaswamy Govindan
منشور في 2018

احصل على النص الكامل
احصل على النص الكامل

دورية

2

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

بواسطة Johan F. Vansteenkiste, Jean Luc Canon, Filippo De Braud, Francesco Grossi, Tommaso De Pas, Jhanelle E. Gray, Wu Chou Su, Enriqueta Felip, Hiroshige Yoshioka, Cesare Gridelli, Grace K. Dy, Sumitra Thongprasert, Martin Reck, Paola Aimone, Gena Atalla Vidam, Pantelia Roussou, Ying A. Wang, Emmanuelle Di Tomaso, Jean Charles Soria
منشور في 2018

احصل على النص الكامل
احصل على النص الكامل

دورية

3

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

بواسطة Johan F. Vansteenkiste, Jean Luc Canon, Filippo De Braud, Francesco Grossi, Tommaso De Pas, Jhanelle E. Gray, Wu Chou Su, Enriqueta Felip, Hiroshige Yoshioka, Cesare Gridelli, Grace K. Dy, Sumitra Thongprasert, Martin Reck, Paola Aimone, Gena Atalla Vidam, Pantelia Roussou, Ying A. Wang, Emmanuelle Di Tomaso, Jean Charles Soria
منشور في 2018

احصل على النص الكامل
احصل على النص الكامل

دورية

4

Pembrolizumab plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer with PDL1 Tumor Proportion Score ‡ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Pembrolizumab plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer with PDL1 Tumor Proportion Score ‡ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

بواسطة Michael Boyer, Mehmet A.N. Şendur, Delvys Rodríguez-Abreu, Keunchil Park, Dae Ho Lee, Irfan Çiçin, Perran Fulden Yumuk, Francisco J. Orlandi, Ticiana A. Leal, Olivier Molinier, Nopadol Soparattanapaisarn, Adrian Langleben, Raffaele Califano, Balazs Medgyasszay, Te Chun Hsia, Gregory A. Otterson, Lu Xu, Bilal Piperdi, Ayman Samkari, Martin Reck
منشور في 2022

احصل على النص الكامل

مقال